Andolast
Andolast (CR 2039) is an anti-allergic agent. Andolast can inhibit cAMP-phosphodiesterase with an IC50 value of 50 μM. Andolast can be used for the research of asthma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 143330-46-5
- 화학식: C15H11N9Na2O
- 분자량:379.29
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
In Vivo
CR 2039 (10-100 mg/kg; i.v. or i.m.) inhibits the microvascular permeability changes in a model of allergic conjunctivitis in sensitized guinea-pigs[1].
CR 2039 (0-1000 μM; i.v.) inhibits dose dependently guinea-pig lung cAMP-phosphodiesterase with an IC50 value of 50 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Hartley guinea-pigs (300-500 g) [1]
-
Dosage:10-100 mg/kg
-
Administration:I.M; I.V.
-
Result:Showed dose-related significant protection against lgE-dependent bronchial anaphylaxis induced by aerosolized antigen in anesthetized guinea-pigs.
Delayed dose dependently the onset of bronchoconstriction induced by aerosolized antigen.
Chemical Information
-
CAS No. 143330-46-5
-
분자량 379.29
-
화학식 C15H11N9Na2O
-
SMILES
O=C(C1=CC=C(C2=NN=NN2)C=C1)NC3=CC=C(C4=NN=NN4)C=C3.[Na].[Na]
-
Synonyms
CR 2039; Dizolast
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
용액&용해도
In Vitro:
DMSO : 11.36 mg/mL (29.95 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
순도&문서
References
[1]. Revel L, Colombo S, Ferrari F, Folco G, Rovati LC, Makovec F. CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma. Eur J Pharmacol. 1992;229(1):45-53. [Content Brief]
[2]. Czuczwar SJ, Gasior M, Kozicka M, Pietrasiewicz T, Turski WA, Kleinrok Z. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. Eur Neuropsychopharmacol. 1998;8(3):233-238. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6365 mL | 13.1825 mL | 26.3650 mL | 65.9126 mL |
| 5 mM | 0.5273 mL | 2.6365 mL | 5.2730 mL | 13.1825 mL | |
| 10 mM | 0.2637 mL | 1.3183 mL | 2.6365 mL | 6.5913 mL | |
| 15 mM | 0.1758 mL | 0.8788 mL | 1.7577 mL | 4.3942 mL | |
| 20 mM | 0.1318 mL | 0.6591 mL | 1.3183 mL | 3.2956 mL | |
| 25 mM | 0.1055 mL | 0.5273 mL | 1.0546 mL | 2.6365 mL |